

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPROVAL OF CLINICAL TRIAL FOR INNOVATIVE MEDICINE
“TRD205 (AT2R RECEPTOR ANTAGONIST)” TABLET

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “TRD205 (AT2R receptor antagonist)” Tablet self-developed by the Group has been approved by the National Medical Products Administration of China to commence clinical trials for the treatment of neuropathic pain. Previously, TRD205 Tablet has been approved by the United States Food and Drug Administration (FDA) to commence clinical trials.

TRD205 Tablet is a novel antagonist with high selectivity for the angiotensin II type 2 receptor (AT2R) and is intended to be tested in clinical trials for indications such as painful diabetic peripheral neuropathy, postherpetic neuralgia, trigeminal neuralgia and postoperative chronic pain. AT2R inhibitor is expected to become a potential blockbuster in the field of neuropathic pain, as there is no similar product available worldwide yet.

Neuropathic pain is a very common type of chronic pain with complex clinical manifestations, most of which last for more than 3 months. The characteristics of pain are not all the same, with burning or fire-like pain, electric shock-like pain, pinprick-like pain, and tearing pain being more common. Neuropathic pain seriously affects the quality of life of patients and causes intolerable suffering, and studies have shown that the prevalence of neuropathic pain in the general population is as high as 8%¹. Currently, clinical medications are mainly opioids and targeted ion-gated channel drugs, which benefit only one quarter of the patients. The activation of AT2R, which is expressed in peripheral/cutaneous macrophages (MΦs), is the key to the sensitization of pain in the site of neurological injury. The activation of AT2R in MΦs triggers the production of reactive oxygen/nitrogen species, which in turn induces calcium influx in sensory neurons of the dorsal root ganglion (DRG), inducing pain hypersensitivity.

The AT2R-targeted drug market has significant potential and in 2023, Lilly acquired development rights to an AT2R inhibitor currently in clinical phase I and other antibody candidates targeting the same receptor, for a total consideration of up to US\$630 million. The Group's self-developed TRD205 has a novel molecular structure and has shown analgesic effects in various peripheral neuropathic pain models, effectively relieving neuropathic pain, inflammatory pain and cancer pain. TRD205 has demonstrated a favourable safety profile in preclinical safety evaluations. The filing of TRD205 will expand the Group's product pipeline in the field of analgesia, addressing an urgent clinical need and bringing a new therapeutic option to the general population of patients suffering from neuropathic pain.

Source of information:

- 1) *Thomas R. Tolle. Challenges with current treatment of neuropathic pain. European journal of pain supplements. 2010; 4: 161-165*

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 27 December 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.